Gilead Sciences Inc (GILD)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell

$101.13

Buy

$101.53

arrow-down$-2.39 (-2.30%)

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
Prices updated at 13 May 2025, 11:13 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up1.61%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Mr. Daniel P. O'Day
CEO
Mr. Daniel P. O'Day
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
17,600
Head office
333 Lakeside Drive
Foster City
United States
94404
mobile
+1 650 574-3000
letter
investor_relations@gilead.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Ms. Diane E. Wilfong
Interim Corporate Controller and Interim Chief Accounting Officer
-----
Mr. Andrew D. Dickinson
Chief Financial Officer
1.08m--8.11m-
Mr. Anthony Welters
Lead Independent Director
0.16m--0.47m-
Dr. Jacqueline K. Barton, PhD
Independent Director
0.12m--0.43m-
Mr. Javier J. Rodriguez
Independent Director
0.10m--0.39m-
Dr. Ted W. Love, M.D.
Independent Director
0.08m--0.48m-
Mr. Harish Manwani
Independent Director
0.12m--0.42m-
Ms. Kelly Anne Kramer
Independent Director
0.14m--0.43m-
Mr. Daniel P. O'Day
Chairman of the Board and Chief Executive Officer
1.77m--23.69m-
Dr. Sandra J. Horning, M.D.
Independent Director
0.13m--0.43m-
Dr. Dietmar Berger, M.D.,PhD
Chief Medical Officer
-----
Dr. Jeffrey A. Bluestone, PhD
Independent Director
0.10m--0.41m-
Ms. Johanna Mercier
Chief Commercial Officer
1.15m--8.61m-
Ms. Deborah H. Telman
Executive Vice President, Corporate Affairs and General Counsel
0.97m--6.07m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock Inc120,355,8410.22496-1579953-1.29572530 Apr 20259.67
Vanguard Group Inc117,470,8250.2379719424331.68134730 Apr 20259.44
Capital Research and Management Company107,391,07326.63271-21343746-30 Apr 20258.63
Capital World Investors71,706,3621.00552-4842566-6.32610630 Apr 20255.76
State Street Corp60,381,7550.220042100640.34910830 Apr 20254.85

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
16 Dec 2024-Mr. Andrew D. Dickinson91.96781,660132,373--
10 Dec 2024-Mr. Andrew D. Dickinson--142,559--
10 Dec 2024-Mr. Andrew D. Dickinson--35,487--
10 Dec 2024-Mr. Andrew D. Dickinson92.34155,685140,873--
10 Dec 2024-Mr. Daniel P. O'Day--506,290--
10 Dec 2024-Mr. Daniel P. O'Day--104,977--
10 Dec 2024-Mr. Daniel P. O'Day92.34439,723501,528--
10 Dec 2024-Ms. Johanna Mercier--36,193--
10 Dec 2024-Ms. Johanna Mercier--76,879--
10 Dec 2024-Ms. Johanna Mercier92.34160,57975,140--
10 Dec 2024-Dr. Merdad V. Parsey, M.D.,PhD--36,753--
10 Dec 2024-Dr. Merdad V. Parsey, M.D.,PhD92.34163,53482,850--
10 Dec 2024-Dr. Merdad V. Parsey, M.D.,PhD--84,621--
10 Dec 2024-Ms. Deborah H. Telman92.3428,25621,312--
10 Dec 2024-Ms. Deborah H. Telman--28,394--
10 Dec 2024-Ms. Deborah H. Telman--21,618--
10 Dec 2024-Ms. Sandra Patterson--12,282--
10 Dec 2024-Ms. Sandra Patterson--37,486--
10 Dec 2024-Ms. Sandra Patterson92.3437,67537,078--
29 Nov 2024-Mr. Andrew D. Dickinson92.7611,867,119138,919--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.